Organization (Other)
Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
ClinicalTrials.gov lists Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) as lead sponsor of 19 trials. It has 3 approved assets.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 0 registered with a 2026 start date. The dashed outline is the pace from the 0 registered with a start date through September, planned starts included, not adjusted; not a forecast. No forecast is made for this organization: it averages 0.0 trial starts a year over the five years to September, under the 5 a year the method needs.
Logo Merck & Co., via Wikimedia Commons, Public domain. Shown to identify the organization; it may be a registered trademark.
This page covers Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA): 19 lead-sponsored trials and 0 legal-entity registrations.
Related companies are recorded in the same corporate group by GLEIF, ROR or a curator but are not grouped here; they are listed below with their own counts and are not included in the figures above.
Disease areas (4)
Shown in this order: most trials first (counted at this company's own legal-entity record, not the consolidated group).
| Disease area | Trials |
|---|---|
| Cellulitis | 1 |
| Erysipelas | 1 |
| Inflammation | 1 |
| Streptococcal Infections | 1 |
Trials by start year as sponsor or collaborator (5)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2012 | 5 |
| 2011 | 4 |
| 2010 | 4 |
| 2009 | 2 |
| 2008 | 4 |
Recruitment duration, a model prediction: none of the 19 trials evaluated at the 2026-10-09 snapshot is predicted and still running. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Approved assets (3)
Shown in this order: max phase first.
| Drug | Trials |
|---|---|
| TR-701 FA | 8 |
| LINEZOLID | 3 |
| Tedizolid | 1 |
Biomarker capability evidence (4)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| CD4 | Trial sponsor | Named in trial exclusion criteria |
| SPDEF | Trial sponsor | Named in trial exclusion criteria |
| CD4 | Trial sponsor | Mentioned in trial text |
| SPDEF | Trial sponsor | Mentioned in trial text |
Not on this page
Checked, with nothing recorded for this organization: companies grouped under this page, active development programs, sponsor delivery record, sec-reported annual financials, financing and grant events, fda warning letters, fda untitled letters, fda inspection record, fda recalls, fda import refusals, manufacturing and distribution sites, climate targets, as filed, workforce and board diversity, as filed, organization relationships, and clia clinical laboratory certificates.
Counted at group level under Merck & Co., Inc.: journals published in, us granted patents, latest dated events, and biomarkers this organization publishes on.